P3Therapeutics
1 known investors
P3 Therapeutics is developing a new class of anti-inflammatory small chemical molecules and works with partners on a humanized gut-entheseal organ-on-chip platform to study their mechanism of action, pharmacokinetics, pharmacodynamics, and biomarkers. The work is part of an application to the EUROSTARS 3 program under the TRIGG3R project.
BiotechDeep TechHealthtech